HaystackAnalytics Launches 'TB One' to Boost India's TB Control Efforts

HaystackAnalytics has launched 'TB One,' a Make-in-India solution aimed at improving TB diagnosis through next-generation sequencing (NGS) in any diagnostic laboratory or hospital. This comprehensive package features a pre-sequencing kit for whole genome sequencing (WGS), the innovative ‘Omega TB’—HaystackAnalytics’ proprietary clinical reporting tool—and on-demand availability of 2GB of sequencing data.

In a single, standardized report, the Omega TB program provides a thorough clinical report that addresses heteroresistance, mixed infections, nontuberculous mycobacteria (NTM), and resistance to 18 anti-TB medications. The goal of "TB One" is to enhance TB management and fortify India's battle against the illness by providing healthcare providers with accurate, data-driven information.

Dr. Rajendra Prasad, a pulmonologist with more than 51 years of expertise in TB treatment and research, and Dr. Anirvan Chatterjee, co-founder and CEO of HaystackAnalytics, have revealed the solution. This occurred on March 19, 2025, during the Indian Council of Medical Research's (ICMR) India Innovation Summit: Pioneering Solutions to End TB.

This technology would make genomics-based TB testing more widely available and scalable by allowing current labs to transition to NGS testing for TB without requiring major infrastructure modifications. This solution meets a pressing need to convert molecular diagnostic labs into cutting-edge genomic facilities and is in perfect harmony with HaystackAnalytics' objective to make genomics accessible, relevant, and inexpensive.